ZYME earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -17.06. Updated 2026-07-23.
Zymeworks (ZYME) Research Hub
Zymeworks (ZYME) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 26.24 USD (-3.35%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -17.06, market cap 1.73B. This hub links to the full technical, earnings and options research available for ZYME.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 26.24 USD (-3.35%) |
| 52-week range | 21.8 USD – 31.34 USD |
| Trend regime | Range |
| 14-day RSI | 58.8 (Bullish) |
| Trailing P/E | -17.06 |
| Market cap | 1.73B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for ZYME
Covered Call on ZYME: how it works, illustrative setup around the real 26.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ZYME: how it works, illustrative setup around the real 26.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ZYME: how it works, illustrative setup around the real 26.24 USD price, max profit/loss, breakeven and when to use it. Educational.
ZYME technical analysis: range, last 26.24 USD, RSI 58.8, 52w range 21.8 USD–31.34 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ZYME in?
Zymeworks (ZYME) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ZYME in an uptrend or downtrend?
As of 2026-09-11, ZYME is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ZYME's trailing P/E ratio?
ZYME's trailing P/E is -17.06, with a market cap of 1.73B. See the earnings research page for full valuation detail.
When does ZYME next report earnings?
ZYME is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.44833 USD.